Abstract Background: The rates of angioedema amongst African American patients using angiotensin- converting- enzyme- inhibitors (ACE-I) are five times greater than non-African American counterparts (01.-07 percent vs. 0.5-3.5 percent). Although ACE-I agents are widely prescribed, they have less therapeutic control in hypertension amongst this group of patients and high incidences of life threating side effects. Methods: The purpose of this quality improvement (QI) project was to assess provider knowledge related to established guidelines from the Joint National Committee (JNC) on hypertension management, as well as their knowledge of the side effects of ACE-I for African American patients. A pre interventions survey was conducted to assess knowledge of established guidelines for hypertension management and risks associated with use of ACE-I in African American patients. The staff was then educated on current guidelines as well as where to access them, and also on the risks of ACE-I and alternative options for African American patients and a post intervention survey was issued to assess knowledge gained from the intervention. Results: Following the educational intervention, all participants were able to identify resources related to guidelines for hypertensive management. However, only 75% of staff were able to recall potential adverse side effects of ACE-I use in African American patients. Conclusion: The results of this QI project support the effectiveness of an educational program addressing ethnic considerations in the prescribing of ACE-I for African American patients. Keywords: African American, angioedema, hypertension, ACE-I